Evidence map›Paper›PMID 28861636›Full record

Observational studyOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2017

Self-perception of fracture risk: what can it tell us?

A E Litwic, J E Compston, A Wyman, E S Siris, S H Gehlbach, J D Adachi, R Chapurlat, A Díez-Pérez, A Z LaCroix, J W Nieves and 13 more

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Systematic screening using FRAXOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Trial
  2. Review
  3. Article
  4. Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Few fragility fracture patients perceive that their bone health is affected by their comorbidities and medications.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Article
  9. Introducing mobile fracture prevention services with DXA in Northern Scotland: a comparative study of three rural communities.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Article
  10. Article
  11. Patients' reasons for adhering to long-term alendronate therapy.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 9 countries.

A E LitwicMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
J E CompstonCambridge Biomedical Centre, Cambridge, UK.
A WymanCenter for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA.
E S SirisDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
S H GehlbachCenter for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA.
J D AdachiSt. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.
R ChapurlatINSERM U831, Division of Rheumatology, Hôpital E. Herriot, Université de Lyon, Lyon, France.
A Díez-PérezHospital del Mar-IMIM-Autonomous, University of Barcelona, Barcelona, Spain.
A Z LaCroixFred Hutchinson Cancer Research Center, Seattle, WA, USA.
J W NievesHelen Hayes Hospital and Columbia University, West Haverstraw, NY, USA.
J C NetelenbosDepartment of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
J PfeilschifterDepartment of Internal Medicine III, Alfried Krupp Krankenhaus, Essen, Germany.
M RossiniDepartment of Rheumatology, University of Verona, Verona, Italy.
C RouxCochin Hospital, Paris Descartes University, Paris, France.
K G SaagUniversity of Alabama-Birmingham, Birmingham, AL, USA.
S SilvermanDepartment of Rheumatology, Cedars-Sinai/UCLA, Los Angeles, CA, USA.
N B WattsBone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA.
S L GreenspanUniversity of Pittsburgh, Pittsburgh, PA, USA.
L MarchFaculty of Medicine and Department of Public Health, University of Sydney, Sydney, Australia.
C L GregsonMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
C CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
E M DennisonMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK. emd@mrc.soton.ac.uk.
Global Longitudinal Study of Osteoporosis in Women (GLOW) Investigators
University of Massachusetts Chan Medical School · USSouthampton General Hospital · GBCedars-Sinai Medical Center · USDélégation Paris 5 · FRThe University of Sydney · AUUniversité Claude Bernard Lyon 1 · FRAlfried Krupp Hospital · DEFred Hutch Cancer Center · USHelen Hayes Hospital · USMRC Lifecourse Epidemiology Unit · GBSouthmead Hospital · GBUniversitat Autònoma de Barcelona · ESUniversity of Pittsburgh · USUniversity of Verona · IT

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
Medical Research Council G0400491Medical Research Council MC_U147574212Medical Research Council MC_U147574234Medical Research Council MC_U147574237Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1NIA NIH HHS P30 AG024827Versus Arthritis 19583
6 · The paper itself

Abstract

In this study, we report that self-perception of fracture risk captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is associated with improved medication uptake. It suggests that adequate appreciation of fracture risk may be beneficial and lead to greater healthcare engagement and treatment.

introductionThis study aimed to assess how well self-perception of fracture risk, and fracture risk as estimated by the fracture prediction tool FRAX, related to fracture incidence and uptake and persistence of anti-osteoporosis medication among women participating in the Global Longitudinal study of Osteoporosis in Women (GLOW).

methodsGLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America and Australia. Aged ≥ 55 years, 60,393 women completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk (SPR). Annual follow-up included self-reported incident fractures and anti-osteoporosis medication (AOM) use. We calculated FRAX risk without bone mineral density measurement.

resultsOf the 39,241 women with at least 1 year of follow-up data, 2132 (5.4%) sustained an incident major osteoporotic fracture over 5 years of follow-up. Within each SPR category, risk of fracture increased as the FRAX categorisation of risk increased. In GLOW, only 11% of women with a lower baseline SPR were taking AOM at baseline, compared with 46% of women with a higher SPR. AOM use tended to increase in the years after a reported fracture. However, women with a lower SPR who were fractured still reported lower AOM rates than women with or without a fracture but had a higher SPR.

conclusionsThese results suggest that SPR captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is also associated with improved medication uptake.

Indexed as

Health Knowledge, Attitudes, PracticeSelf ConceptAgedBone Density Conservation AgentsComorbidityDrug MonitoringDrug UtilizationFemaleFollow-Up StudiesHumansIncidenceMedication AdherenceMiddle AgedOsteoporosis, PostmenopausalOsteoporotic FracturesRisk AssessmentBone Density Conservation AgentsAdherenceFracture riskFRAXOsteoporosisTreatment

Identifiers

PMID28861636
PMCPMC5759929
OpenAlexW2753761269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.